YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT06458010), and the data has been published on medRxiv. YOLT-101 is an investigational in vivo base editing therapy for the treatment of heterozygous familial hypercholesterolemia...
Sonitus Medical and BHM Establish Strategic Cooperation
SHANGHAI, April 28, 2025 /PRNewswire/ -- Sonitus Medical has entered into a strategic cooperation with BHM, a renowned European manufacturer of bone conduction hearing devices. The two companies will engage in deep collaboration across product development, manufacturing, regulatory approval, marketing, and sales. Under the agreement, Sonitus Medical grants BHM the commercialization rights outside of China for two innovative...
2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
SHANGHAI, April 28, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a...
Hong Kong Mental Wellness Association Presents the First Charity Concert Combining Music and Story Sharing: “You’ve Got a Friend”
HONG KONG, April 28, 2025 /PRNewswire/ -- In response to the urgent need for emotional health awareness among students, as highlighted in the Hong Kong Department of Health's "Student Health Service Annual Report 2023/24," which revealed that 2.2% and 1% of students had planned or attempted suicide in the past year, the Hong Kong Mental Wellness Association recently...
ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting
SUZHOU, China, April 28, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Research ("AACR") annual meeting. ...
Nona Biosciences’ Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 28, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisomerase 1 inhibitor (TOP1i)-based antibody-drug conjugate (ADC) targeting mesothelin (MSLN), at the AACR Annual Meeting 2025. This ADC...
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs)...
Everest Medicines Announces the “B” Marker Removal from Company’s Stock Code, Effective May 2, 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the "B" marker will cease to be affixed to the Company's stock short name, effective May 2, 2025. The removal of "B" marker was granted by The...
ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups
Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences...
International Symposium in Chengdu Advances TCM and Wellness Industry Integration
CHENGDU, China, April 26, 2025 /PRNewswire/ -- The 2025 International Symposium on TCM Formulas, Medicinals and Health Preservation kicked off on April 26 at the Luxelakes Eco-City in Chengdu, Sichuan province, attracting TCM experts, scholars, industry leaders, and government representatives from over 20 countries. The two-day event was sponsored by the Zhongguancun Yanhuang TCM Technology...
